|Videos|May 17, 2021
Second Opinion: ASH 2020 Takeaways for Myelofibrosis
Author(s)OncLive
Dr. Ruben Mesa and Dr. Aaron Gerds discuss the current landscape of myelofibrosis and key takeaways from the 2020 ASH Annual Meeting and Exposition in this rare cancer.
Dr. Ruben Mesa and Dr. Aaron Gerds discuss the current landscape of myelofibrosis and key takeaways from the 2020 ASH Annual Meeting and Exposition in this rare cancer. They also provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.
Related Articles
Deep Dive: Into Improving Patient Outcomes Through AIAugust 16th 2023
Behind the Science: Behind Chemotherapy ShortagesAugust 15th 2023
Deep Dive: Into Types of ChromatographyAugust 15th 2023
Deep Dive: Into Clinical Trials & Reproductive HealthAugust 4th 2023
Deep Dive: Into Diabetic RetinopathyAugust 3rd 2023
Deep Dive: Into AHN’s Fertility ClinicAugust 2nd 2023
